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ABSTRACT
The nutritional and health status of dietary supplements users have been widely studied in other countries. However, few
studies have examined lipid-lowering supplements users in Malaysia. Findings are inconsistent concerning the effectiveness
of lipid-lowering supplements on cholesterol levels. Hence, this study was aimed to determine the health (physical, mental
and social levels) and nutritional status (BMI, blood pressure and lipid profile) of lipid lowering supplement users. A cross
sectional study of one hundred lipid lowering supplement subjects was conducted; body weight, height, blood pressure and
lipid profile were measured. The results found that majority of the supplement users had normal physical, mental, and social
health levels and normal level of lipid profiles, except for HDL-c and LDL-c than the non-users. Results also show an
association (p<0.005) between lipid lowering groups (fish oil and flaxseed oil, soluble fiber and phytosterol) and body fat
percentage (p=0.002). These findings suggest that in general lipid lowering supplements may have beneficial influence on the
mental and social health status, and nutritional status (i.e. TC and TG, blood pressure, body fat percentage).
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INTRODUCTION
Garlic supplement, ginseng, ginkgo biloba, fish
oils, soy supplements and flaxseed oil were among
the most commonly consume lipid lowering
supplements among cardiovascular disease (CVD)
patients (Yeh et al., 2006). Lipid-lowering
supplements help to reduce or prevent an increase
in blood serum cholesterol levels (Chen et al.,
2010). Studies on the nutritional status of lipid
lowering supplement users have indicated that lipid-
lowering supplements generally significantly
improve lipid profile in terms of total cholesterol
(TC), high lipid lipoprotein density cholesterol
(HDL-c), triglycerides (TG), and low lipoprotein
density cholesterol (LDL-c) (Mohamad et al., 2014;
Yeap et al., 2014) without a substantial risk of
muscle pain (Hainer, 2009). In contrast to the lipid
lowering supplements, the currently available lipid-
lowering drugs (e.g. statins) act in reducing low-
density lipoproteins cholesterol (LDL-c) levels by
inhibiting the action of 3-hydroxy-3methylglutaryl
coenzyme A (HMG-CoA) reductase (Opie & Dphil,
2015). However, cholesterol itself is not merely a
final product, but also an intermediate to a suite of
additional products such as sex steroids, bile acids,
and vitamin D, which are all affected by statin
administration. Muscle adverse effects are
emphasized, as they are the best recognized adverse
effect of statins (Golomb & Evans, 2008).
Health status can be defined as the range of
manifestation of diseases in a given patient
including functional limitation, symptoms
appeared, and quality of life, in which quality of life
is the divergence between reality and ideal function
(Rumsfeld, 2002). Poor health status linked to
physical and mental illness such as coronary heart
disease and depression, respectively (Mental Health
Foundation, 2011). Previous studies have revealed
that the health status of lipid lowering supplement
users were being improved in terms of physical
(blood pressure), mental (depression symptoms) and
social health among hypertensive subjects, older
adults, and the general public (Ried et al., 2013;
Ehrlich, 2015; Uchino, 2006).
However, studies have also revealed that lipid-
lowering supplements do not significantly improve
lipid profile (Park et al., 2012; Ottestad et al., 2013).
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Inconsistent findings for the effectiveness of lipid-
lowering supplements on reducing cholesterol
remain controversial. For instance, no significant
reduction was found in LDL-c levels with the
consumption of phytosterol capsules (2 g/day) as
compared to the placebo among hyper-
cholesterolemia subjects (Ottestad et al., 2013).
However, a dose of 3 g/day lowers LDL-c by 15%
according to Gylling and Simonen (2015) among
type 2 diabetes and overweight-obese subjects with
metabolic syndrome. These differences may be due
to the different dose of supplements, dissimilarity
of research design, and other factors such as the
varying lifestyle and dietary habits of respondents
in different studies.
Despite this, few studies have been carried out
on the nutritional status of lipid lowering supple-
ment users in Malaysia compared to studies done
on nutritional status of general dietary supplements
users. Therefore, the current study is important to
further investigate the health benefits of lipid-
lowering supplements on lipid profile, BMI, blood
pressure, mental and social health and risk factors
of CVD and hypertension among healthy
population. The findings of the present study could
provide information to health-related organizations
or health government ministries to further
investigate the efficacy of lipid-lowering supple-
ments in lowering blood serum cholesterol. This
study aims to determine the health and nutritional
status of lipid lowering supplement users, the health
benefits of lipid lowering supplement, and the
association between different types of lipid-
lowering supplements and the health and nutritional
status of supplement users.
MATERIALS AND METHODS
This present cross-sectional study was conducted
in Kuala Lumpur this study site was chosen as it is
highly populated and may accurately estimate
population values (Murray & Kujundzic, 2005).
Based on the Yamane formula for determining
number of sample size, a total of 100 lipid
lowering supplement users in Kuala Lumpur were
conveniently selected (Yamane, 1967). Respondents
aged 18 years old and above, and with the
consumption of lipid lowering supplement were
chosen. This survey carried out for 2 months starting
from 1st July until 31st August 2015. The data was
collected during weekends and weekdays. This
study was registered in the National Medical
Research Register (NMRR) for ethical approval
(NMRR-15-829-24996). All respondents signed an
informed consent form prior to data collection.
This study used a bilingual self-administered
validated questionnaire consists of five sections:
a) socio-demographic information; b) general
background; c) mental health assessment; d) social
health assessment; and e) nutritional status
assessment. Section A of questionnaire consisted
of questions pertaining to socio-demographic
variables. Data such as gender, age, race, educa-
tional level, marital status and monthly income were
assessed and the scale used were nominal scale
except for age which was ratio scale. Section B
obtained information on smoking habits, alcohol
consumption, types of lipid-lowering supplements
intake, existing diseases, family history of diseases
and current level of physical activity. The scale
used in section B was a nominal scale.
In section C, subjects were assessed for their
mental health with the Depression Anxiety and
Stress Scale (DASS) to test stress and depression
levels based on a 4-point rating scale developed by
the Australian Centre for Post-Traumatic Mental
Health; 0 = Did not apply to me at all, 1 = Applied
to me to some degree, or some of the time, 2 =
Applied to me to a considerate degree, or a good
part of time, and 3 = Applied to me very much, or
most of the time. Their total scores were calculated
in order to analyze their stress and depression
condition. The scores obtained were multiplied by
2 (Lovibond & Lovibond, 1995). Table 1 shows the
scoring information for DASS severity ratings.
For Section D, subjects were assessed for their
social health using Cohen & Hoberman’s (1983) 12-
item scale to measure perceptions of social support.
For items 1, 2, 7, 8, 11 and 12, assign each response
a numerical value as follows: Definitely true = 0;
probably true = 1; probably false = 2; definitely
Table 1. Scoring information for DASS Severity Ratings
Stress Depression
(Q1-7) (Q8-14)
Range in % Range in %
Normal 0.0 – 33.3 0 – 21.4
Mild 35.7 – 42.9 23.8 – 31.0
Moderate 45.2 – 59.5 33.3 – 47.6
Severe 61.9 – 78.6 50.0 – 64.3
Extremely Severe 81.0 – 100.0 66.7 – 100.0
Note: Depression Anxiety and Stress Scale (DASS) items; Q1=I
found it hard to calm down, Q2=I tended to over-react to situations,
Q3=I felt that I was using a lot of nervous energy, Q4=I found
myself getting agitated, Q5=I found it difficult to relax, Q6=I was
intolerant of anything that kept me from getting on with what I was
doing, Q7=I felt that I was rather touchy, Q8=I couldn’t seem to
experience any positive feeling at all, Q9=I found it difficult to work
up the initiative to do things, Q10=I felt that I had nothing to look
forward to, Q11=I felt down-hearted and blue, Q12=I was unable to
become enthusiastic about anything, Q13=I felt I wasn’t worth much
as a person, and Q14=I felt that life was meaningless.
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false = 3. For the remaining items assign each
response a numerical value as follows: Definitely
true = 3; probably true = 2; probably false = 1;
definitely false = 0. The scores will be summed up
and classified into either low (0-12 points),
moderate (13-24 points), or high levels (25-36
points) of social support accordingly.
For the last section, the respondents were
evaluated for their nutritional status via anthro-
pometric, biochemical, clinical and dietary
assessments. Height, body weight and body fat were
measured using a measuring tape and Karada scan
respectively. BMI was calculated from the Quetelet’s
formula: BMI (kg/m2) = body weight (kg) / height
(m2) (WHO, 2006). Lipid profiles, including total
cholesterol (TC), high density lipoprotein (HDL-c),
triglyceride (TG) and low-density lipoprotein (LDL-
c), were evaluated. Respondents were tested for their
lipid profile (TC, HDL, TG and LDL in whole blood)
using Cardiocheck Pa and PTS Panels Lipid Panel
test strips (PTS Diagnostics, USA). TC, HDL-c, TG,
LDL-c were then categorized based on the ATP III
US National Cholesterol Education Program (NCEP)
(2001). In clinical assessment, blood pressure was
measured using an Omron Automatic Blood Pressure
Monitor (Omron Healthcare, US) and classified
according to the categorization used in NHMS III
(Ministry of Health Malaysia, 2006). In diet
assessment, dietary intake was measured by using
food frequency questionnaire (FFQ), which uses an
ordinal scale. Food intake scores were calculated
based on Chee et al. (2010) and was classified into
either extreme low (< 25.5%), low (25.5–59.9%),
medium (60–79.9%) or high intake (80–100%). The
data was analyzed using SPSS version 20.0.
Kolmogorov-Smirnov test was used to check
normality prior analysis. Frequency and percentage
were used to depict the descriptive distributions of
socio-demographic, mental health, social health and
nutritional status findings. Chi-square test was used
to determine the association between lipid-lowering
supplements and lipid profile, physical health,
mental health, social health and nutritional status
if conditions fulfilled, while the Fischer Exact test
was used if two conditions of chi-squares (no more
than 20 percent of cells in the contingency table
should have expected values less than five and no
cell has an expected value of less than one) were
not fulfilled (Connolly, 2007). P value less than 0.05
was considered as significant.
RESULTS AND DISCUSSION
Socio-demographic characteristics of respondents
Table 2 shows the socio-demographic charac-
teristics of respondents. More than half (59%) of
respondents were female and most were between 18
to 34 years old. According to Petry (2002), young
adults are those between 18 to 35 years old.
Therefore, the proportion of young adults in this
study was approximately 61%, which is sufficient
to represent the sample population (young adults)
in the present study. Among the three main races,
half of the lipid-lowering supplements users were
Chinese (50%), followed by Malay (37%) and
Indian (12%). About 64% of the respondents had
higher educational level, as either diploma or degree
holders. Out of the 10 lipid-lowering supplements,
fish oil was the most popular. More than half of the
respondents were lightly active in their daily life,
followed by sedentary lifestyle.
Mental and social health characteristics of
respondents
Table 3 shows the mental and social health
characteristics of lipid lowering supplement users.
Table 2. Socio-demographic characteristics of respon-
dents (n = 100)
Characteristics N %
Gender
Male 41 41.0
Female 59 59.0
Age group
(Median=30, Q1=23; Q3=43)
18-24 37 37.0
25-34 24 24.0
35-44 15 15.0
45-54 15 15.0
55-64 9 9.0
Race
Malay 37 37.0
Chinese 50 50.0
Indian 12 12.0
Others 1 1.0
Education
Primary 5 5.0
Secondary 23 23.0
Diploma 12 12.0
Bachelor degree 52 52.0
Others 8 8.0
Lipid lowering supplement
Fish oil 43 43.0
Ginkgo Biloba 8 8.0
Garlic 4 4.0
Soluble fiber 16 16.0
Red yeast rice extract 5 5.0
Phytosterol 1 1.0
Ginseng 2 2.0
N. sativa and honey mixture 1 1.0
Soy 11 11.0
Flaxseed oil 5 5.0
Others 4 4.0
Perceived physical level
Sedentary 35 35.0
Lightly active 54 54.0
Fairly active 9 9.0
Highly active 2 2.0
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Table 3. Mental and social health characteristics of respondents
Characteristics N % Median (Q1, Q3)
Stress Level (range of score)
Normal (0-7) 75 75.0
Mild (7.5-9) 13 13.0
Moderate (9.5-12.5) 8 8.0 5.00 (3.00, 7.75)
Severe (13-16.5) 2 2.0
Extremely severe (17-21) 2 2.0
Depression level (range of score)
Normal (0-4.5) 66 66.0
Mild (5-6.5) 21 21.0
Moderate (7-10) 10 10.0 3.00 (1.00, 5.00)
Severe (10.5-13.5) 2 2.0
Extremely Severe (14-21) 1 1.0
Social Health level (range of score)
Low (0-12) 6 6.0
Moderate (13-24) 36 36.0 29.00 (27.00, 31.00)
High (25-36) 58 58.0
Abbreviations: Q1 = First quartile and Q3 = Third quartile.
Based on Table 3, the current study showed that
most lipid lowering supplement users were in a
normal mental state and social health levels.
There were two separate parts of the mental
health assessment, namely stress level and
depression level. The stress scale is sensitive to
levels of chronic non-specific arousal. It assesses
difficulty relaxing, nervous arousal, and being easily
upset/agitated, irritable/over-reactive or impatient
while the depression scale assesses dysphoria,
hopelessness, devaluation of life, self-deprecation,
lack of interest/involvement, anhedonia, and inertia
(Lovibond & Lovibond, 1995). Results showed that
the percentages of respondents with normal level
of stress and depression were 75% and 66%,
respectively. This has been seen in the daily
consumption of 1.5-1.8 g DHA in fish oil can
reduced stress and decreased the aggressive
tendencies of young adults, possibly by modulating
stress (Lajtha et al., 2009). Another distinction
example can be seen through ingestion of Ginkgo
biloba standardized extract, 40 to 80 mg, 3 times
daily, can relieved depression. A few studies looking
at ginkgo for treating memory problems in older
adults have been reported to show improvement in
depression symptoms (Ehrlich, 2015).
In terms of social health, about 58% of
respondents were at a high level. According to
Cohen (2004), social support may have indirect
effects on health by enhancing mental health,
decreasing the impact of stress, or fostering a sense
of meaning and purpose in life. Supportive social
ties may trigger physiological effects such as
reduction of heart rate, blood pressure and stress
hormones that are beneficial to health and minimize
unpleasant arousal (Uchino, 2006).
Lipid profile characteristics of respondents
Table 4 shows the lipid profile (TC, HDL-c,
TG and LDL-c) characteristics of lipid lowering
supplement users. Based on Table 4, most
respondents generally had a normal reading for
lipid profile, except for HDL-c and LDL-c, which
were in the moderate and near optimal category,
respectively.
The median levels of TC and TG among users
were 4.72 mmol/L (Q1 = 4.39, Q3 = 4.92) and 1.35
mmol/L (Q1 = 1.12, Q3 = 1.49), which were in the
desirable and normal category, respectively. The
results obtained were similar with previous studies
that reported lipid-lowering supplements users had
a significant decrease in mean serum TC by 0.136
mmol/L and TG by 0.162 mmol/L (Reynolds et al.,
2006); fish oil users had a significant decreased in
TG by 0.34 mmol/L (Eslick et al., 2009); flaxseed
oil users had a significant reduce in TC by 5.0%
(p<0.01) (Kontogianni et al., 2013) and N. sativa
and honey users also had a significant decrease in
TC by 6.2% in the hypercholesteromic group
(Mohamad et al., 2014). However, the levels of lipid
profile of respondents were not determined before
supplementation; thus, the effect cannot be directly
verified.
On the other hand, the median of HDL-c and
LDL-c among users were in the moderate and near
optimal category, respectively. The results obtained
were similar to those of 47 previous studies which
reported that an average dose of 3.25 g/day of
omega-3 fish oils provides very slight increase in
HDL-c (0.01 mmol/L) and LDL-c (0.06 mmol/L)
(16,511 individuals with cardiovascular risk factors)
(Eslick et al., 2009). Phytosterol intake (2 g/day) for
four weeks provided no significant reduction in
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Table 4. Lipid profile and blood pressure characteristics of respondents
Characteristics n % Median (Q1, Q3)
TC category/Value (mmol/L)
Desirable (<5.18) 92 92.0
Borderline to high (5.18-6.20) 4 4.0 4.72 (4.39, 4.92)
High (> 6.20) 4 4.0
HDL-c category/Value (mmol/L)
Low (< 1.04) 12 12.0
Moderate (1.04 – 1.54) 56 56.0 1.40 (1.22, 1.58)
High (> 1.55) 32 32.0
TG category/Value (mmol/L)
Normal (< 1.70) 95 95.0
Borderline to high (1.70-2.25) 2 2.0 1.35 (1.12, 1.49)High (2.26-5.64) 2 2.0
Very high (>5.65) 1 1.0
LDL-c category/Value (mmol/L)
Optimal (<2.59) 41 41.0
Near optimal (2.59-3.35) 50 50.0 2.70 (2.38, 2.97)Borderline high (3.36-4.12) 6 6.0
High (4.13-4.90) 3 3.0
Systolic category/Value (mmHg)
Optimal (< 120) 65 65.0
Normal (< 130) 25 25.0
High Normal (130-139) 7 7.0 116.83 (11.49)
Hypertension class I (140-159) 2 2.0
Hypertension class II (160-179) 1 1.0
Diastolic category/Value (mmHg)
Optimal (< 80) 70 70.0
Normal (< 85) 23 23.0
High Normal (85-89) 5 5.0 77.00 (70.25, 80.00)
Hypertension class I (90-99) 1 1.0
Hypertension class II (100-109) 1 1.0
Abbreviations: Q1 = First quartile; Q3 = Third quartile; TC = Total cholesterol; HDL-c = High density
lipoprotein cholesterol; TG = Triglycerides and LDL-c = Low density lipoprotein cholesterol.
LDL-c levels when compared to the placebo period
(-0.01 mmol/L) and no significant changes were
found in the plasma levels of HDL-c in participants
with TC 4.7-7.7 mmol/L and with fasting TG < 4.0
mmol/L (n=41) (Ottestad et al., 2013). Flaxseed oil
showed no significant effect on LDL-c levels (Shim
et al., 2014).
However, some previous studies reported
contrasting results. Flaxseed oil (15 mL/day) for six
weeks exhibited significant reduction in LDL-c
(-6.7%) of young, healthy, normal weight adults
(n=37) (Kontogianni et al., 2013), while 1200 mg
of red yeast rice at bedtime reduced LDL-c of 25
patients intolerant to daily statins by 21% (-35 ± 25
mg/dL) for > 4 weeks (Venero et al., 2010).
Additionally, 20 to >61 g/day soy protein supple-
mentation was associated with a signification
reduction in mean serum LDL-c (-4.25 mg/dL) and
a significant increase in HDL-c (0.77 mg/dL) in a
meta-analysis of 41 trials with sample size from
4 to 179 normal adults.
Blood pressure characteristics of respondents
Table 4 shows the blood pressure characteristics
of lipid lowering supplement users. The medians of
systolic and diastolic values of users were 116.83
and 77.00 mmHg, respectively, which are both in
the optimal category. This is supported by previous
studies showing that 3 months of ginkgo biloba
intake led to a 6% reduction in systolic blood
pressure and a 21% reduction in diastolic blood
pressure in a slightly older, pre-hypertensive
population (Kudolo, 2000); and that mean systolic
blood pressure was significantly reduced by 11.8 ±
5.4 mmHg in the group of respondents that took two
capsules of garlic supplement over 12 weeks (Ried
et al., 2013).
Body Mass Index and body fat percent charac-
teristic of respondents
Table 5 shows the BMI and body fat percentage
characteristic of lipid lowering supplement users
for male and female separately. The median values
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of BMI for male and female were 24.44 kg/m2 and
22.64 kg/m2, respectively, both in normal weight
category based on the WHO classification. The
mean of body fat in the present study for males was
20.2% while the median for females was 17.2%. The
mean body fat percentage among normal urban
Malaysians for both male and female were 21.0%
and 31.1%, respectively (Chee et al., 1997). In
comparison, body fat percentage for lipid lowering
supplement users, especially females, was lower than
that of normal adults in Malaysia.
Among the 59 female respondents, 37% of them
have lightly to fairly active physical levels. Wu and
O’Sullivan (2011) stated that women generally have
a higher proportion of body fat compared to men.
However, women consume fewer kilojoules per
kilogram lean mass and burn fat more preferentially
during exercise compared with men (Wu &
O’Sullivan, 2011).
According to previous study, there was a
significant reduction in fat mass (-0.5 ± 1.3 kg)
tendency for a decrease in body fat percentage
(-0.4 ± 1.3% body fat) with fish oil supplemental
treatment (Noreen et al., 2010); a study by
researchers at Wake Forest Baptist Medical Center,
for every 10 gram increase in soluble fiber eaten per
day, visceral fat was reduced by 3.7% over five years
(Hairston et al., 2011), which supports the results
obtained showing that their BMI and body fat
percentage were situated at normal category among
users based on WHO classification.
Normal BMI and body fat percentage might
also be influenced by lifestyle patterns, since 65%
of users reported that they are physically active to
highly active. Physical activity increases total
energy expenditure, which can help people stay in
energy balance or even lose weight. In addition, it
decreases fat around the waist and total body fat (Hu,
2008).
Association between lipid lowering supplement
groups with nutritional and health status
Table 6 depicts the associations among lipid
lowering supplement groups relative to the
nutritional and health status among supplement
users. There were no significant associations found
between stress level, depression level, social health
category, HDL-c category and BMI category within
lipid lowering supplement groups. Furthermore,
there were also no significant associations found
among diseases category, blood pressure category,
TC category, TG category and LDL-c category
within lipid lowering supplement groups.
However, there was an association between
body fat percentage and lipid lowering supplement
groups, χ2 (1, N = 100) = 12.86, p < 0.05. These
results are supported by a previous study which
indicated that the fatty acids in fish oil, notably EPA
and DHA, have an effect on the partitioning of fat
between oxidation (fat burning) and storage in the
body. Fatty acids in dietary fat not only influences
hormonal signaling events, but also have a very
strong direct influence on the molecular events that
govern gene expression. It has been shown that the
fatty acids EPA and DHA from fish oil (by affecting
gene expression) inhibit the activities of fat
synthesizing (lipogenic) enzymes (Hannah et al.,
2001), while at the same time stimulating the
activities of key enzymes that govern fat oxidation
(fat burning) (Desvergne & Wahli, 1999). A study
by Couet et al. (1997) found that body fat mass
reduced with dietary fish oil (0.88 ± 0.16 kg)
(p<0.05) using dual-energy X-ray absorptiometry.
Table 5. Body Mass Index and body fat percentage characteristic of lipid lowering supplement users for male and female
respectively
Male (n = 41) Female (n = 59)
Characteristics
n % Median (Q1, Q3) or n % Median (Q1, Q3) orMean (SD) Mean (SD)
BMI category
Underweight 0 0 4 6.8
Healthy weight 17 41.5 24.44 (22.32, 26.97) 26 44.1 22.64 (20.71, 25.73)Overweight 14 34.1 17 28.8
Obese 10 24.4 12 20.3
Body fat category
Less than essential fat 0 0 6 10.2
Essential fat 0 0 11 18.6
Athletes 7 17.1 20.24 (9.93) 22 37.3 17.20 (12.50, 27.60)Fitness 13 31.7 2 3.4
Average 13 31.7 5 8.5
Obese 8 19.5 13 22.0
Abbreviations: SD: Standard deviation; Q1 = First quartile; Q3 = Third quartile and BMI = Body mass index.
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Table 6. Association between lipid lowering supplement groups with nutritional and health status of supplement users
Lipid lowering supplement groups
Variables Fish oil & Soluble fiber Othersa Pearson Chi-squareFlaxseed oil & Phytosterol
N E.C N E.C N E.C
Stress level
Normal 35 36.0 12 12.8 28 26.3 χ2=0.754
Mild to extremely severe 13 12.0 5 4.3 7 8.8 p = 0.686
Depression level
Normal 31 31.7 10 11.2 25 23.1 χ 2=0.893
Mild to extremely severe 17 16.3 7 5.8 10 11.9 p = 0.640
Social Health category
Low & moderate 22 20.2 4 7.1 16 14.7 χ 2=0.287
High 26 27.8 13 9.9 19 20.3 p = 0.238
HDL-c category
Low & moderate 30 32.6 13 11.6 25 23.8 χ2=1.417
High 18 15.4 4 5.4 10 11.2 p = 0.492
BMI category
Underweight & Normal 31 31.2 9 11.1 25 22.8 χ2=1.726
Overweight & Obese 17 16.8 8 6.0 10 12.3 p = 0.422
Body Fat % category
Non-obese 42 37.9 8 13.4 29 27.7 χ2=12.86
Obese 6 10.1 9 3.6 6 7.4 p = 0.002*
Lipid lowering supplement groups
Variables Fish oil & Othersb Pearson Chi-squareFlaxseed oil
N % N %
Diseases category
Yes 6 12.5 11 21.2 χ2=2.235Not sure 5 10.4 8 15.4 p = 0.327No 37 77.1 33 63.5
Lipid lowering supplement groups
Variables Fish oil & Othersb Fischer Exact’s TestFlaxseed oil
N % N %
Blood pressure category
Non-hypertension 48 100.0 49 94.2 p=0.244Hypertension 0 0.0 3 5.8
TC category
Normal & Borderline to high 47 97.9 49 94.2 p=0.340High 1 2.1 3 5.8
TG category
Normal & Borderline to high 48 100.0 49 94.2 p=0.244High & Very high 0 0.0 3 5.8
LDL-c category
Optimal to Borderline to high 47 97.9 50 96.2 p=1.000High 1 2.1 2 3.8
Notes: Othersa mean ginkgo biloba, red yeast rice, ginseng, N. sativa and honey, soy and other supplements. Othersb mean soluble fiber,
phytosterol, ginkgo biloba, garlic, red yeast rice, ginseng, N. sativa and honey, soy and other supplements. Othersa and Othersb were
different in order to fulfill the conditions of Chi-square and Fischer Exact’s test. E.C means expected counts. Statistically significant at
p<0.05 by Chi-square test.
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Besides fish oil, fiber and soy protein intake
tend to show signification association towards body
fat percentage. A previous prospective cohort study
by Tucker and Thomas (2009) stated for each 1 g
increase in total fiber consumed, body fat decreased
by 0.25 percentage points (p<0.01). According to
Guerin-Deremaux et al. (2013), body fat decreased
significantly with 18 g and 24 g soluble fiber
supplementation in 100 overweight adults in China.
A previous study found that soy protein intake was
associated with improved fat oxidation markers
(Morifuji et al., 2006). A study of 83 obese men and
women by Deibert et al. (2004) examined three
treatment groups, including two groups following a
high-soy-protein, low fat diet. The soy protein group
lost more body fat while preserving lean muscle.
These results differ from several studies that
showed no significant association with health and
nutritional status (NCEP, 2001; Morris et al., 1993),
but they are broadly consistent with studies from
Sacks et al., 2006 and Eslick et al., 2009. These
differences may be due to reasons such as the dose
(Racette et al., 2009; Guerin-Deremaux et al., 2013),
duration (Zhu et al., 2014; Allen et al., 2007), and
bioavailability (Holub & Grebow, 2011; Lawson &
Hughes, 1988) of lipid-lowering supplements.
CONCLUSION
This study has identified lipid-lowering supplements
(fish oils, ginkgo biloba, garlic, soluble fiber, red
yeast rice, phytosterol, ginseng, N. sativa and honey,
soy, flaxseed oil and others) users had a normal state
of mental and social health status and nutritional
status in terms of TC and TG, blood pressure for
both systolic and diastolic, BMI (for females) and
body fat percentage for both males and females.
However, it did not influence the HDL-c and LDL-c
levels. The second major finding was that there was
an association between lipid lowering groups and
body fat percentage (p=0.002). These findings
suggest that in general lipid lowering supplements
may have beneficial influence on the mental and
social health status, and nutritional status (i.e. TC
and TG, blood pressure, body fat percentage). These
results must be interpreted with caution as patients
do need to seek advice from medical practitioner
prior to supplement consumption.
It is unfortunate that the study did not include
the duration of supplement consumption among the
respondents, which may affect the measurement of
supplement effectiveness accurately as some
supplements work in long term. An additional
uncontrolled factor is the possibility of other factors
such as unknown food-drug interaction, genotype,
different lifestyle factors and compliance to
supplements use and drug, which may influence the
findings. Thirdly, the study did not evaluate the
lipid profile of respondents before supplementation.
Notwithstanding these limitations, the study
suggests that further investigation on nutritional and
health status of lipid lowering supplements users
by dosage, duration and forms of lipid lowering
supplements need to be carried out. Further studies
may involve high risk subjects such as hyper-
lipidemia, hypertensive or obese patients in a
longitudinal study to observe possible changes over
a period of time. Unknown food-drug interaction
should be investigated to ensure the effectiveness
of lipid lowering supplements. Moreover,
confounding factors such as socio-demographic,
physical activity levels and diet need to be
controlled to solely investigate the effectiveness of
lipid lowering supplements toward health and
nutritional status of subjects. Large randomized
controlled trials on mechanisms of lipid lowering
supplements could provide more definitive
evidence.
In spite of its limitations, the study certainly
adds to our understanding of the health and
nutritional status of lipid lowering supplement
users. This study offers some insight to medical
practitioners, dieticians, nutritionists and health-
related government. Public will be more self-assured
on consuming this kind of supplements and decrease
the dependent on lipid lowering drugs which
consist of adverse side effects subject to medical
approval.
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